MCM
CLDX icon

Moore Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Moore Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,000
Closed -$2.23M – 502
2022
Q4 		$2.23M Buy
50,000
+20,007
+67% +$714K 0.05% 262
2022
Q3 		$843K Buy
29,993
+12,212
+69% +$374K 0.02% 423
2022
Q2 		$479K Hold
17,781
– – 0.01% 433
2022
Q1 		$606K Buy
+17,781
New +$568K 0.02% 451
2021
Q1 		– Sell
-95,000
Closed -$1.66M – 689
2020
Q4 		$1.66M Buy
+95,000
New +$1.71M 0.02% 372

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Moore Capital Management's CLDX Position: Q1 2023 in Review

Moore Capital Management sold out of Celldex Therapeutics (CLDX) in Q1 2023, closing a stake of 50,000 shares — an estimated $2.23M sold.

Moore Capital Management first reported a position in CLDX in Q4 2020 and held it in 5 quarters. The position peaked at $2.23M in Q4 2022. 161 funds tracked by Wall St. Rank hold CLDX as of Q1 2023.

  • Moore Capital Management reported no remaining Celldex Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Moore Capital Management sold 50,000 Celldex Therapeutics shares in Q1 2023, an estimated $2.23M.
  • Moore Capital Management first reported a position in Celldex Therapeutics in Q4 2020 and held it in 5 quarters.
  • Moore Capital Management's Celldex Therapeutics position peaked at $2.23M in Q4 2022.
  • 161 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2023.

Based on Moore Capital Management's 13F filing for Q1 2023, filed 15 May 2023.